Meredith Gunder, MD, MS

Biology is king

Same-Day Multidisciplinary Clinics for Patients With Newly Diagnosed Adult Solid Tumor Cancer: A Systematic Review | JCO Oncology Practice ascopubs.org/doi/10.1200/OP… @InovaSchar

#AudioVisualAbstract : The Relationship Between Area-Level #Marginalization and Overall Survival of Patients with Soft Tissue #Sarcoma in Ontario: A Retrospective Cohort Study rdcu.be/eTboj @MeredithGunder @SyedAAhmad5

The SSO is accepting applications for 2026 committee openings! - Be an active SSO member. - Commit your time + expertise. - Attend the Joint Committee Conference held at the SSO Annual Meeting. Keep an eye on your inbox for the link to apply! Learn more: ow.ly/5Ms950X5PEk

Specialized HPB anesthesia teams could ⬆️outcomes The pushback? ⚠️“They will lose volume (experience) in other surgeries” We put it to the test👀👇🏻 Bottom line: they do not 💭Time to stop hesitating? Make specialized HPB anesthesia happen tinyurl.com/bddedydf @BJSurgery

Our new Surg Onc text for students is finally in print and available! Grateful to @JeffreyFarma for the opportunity and huge appreciation for all the co-authors (too many to tag, you all rock🙏🏻). Check it out on the Amazon store 📚 @AAMCtoday @SocSurgOnc @AmBdSurg

In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research Summary: nej.md/437IXTF

Intra operative revision of +ve margin ⬆️ survival in gastric & GE junction adenoCa ✔️ R0 resection remains crucial ✔️ Even in locally advanced cases, margin revision improves outcomes—esp. in N0/N1 disease 🔗 doi.org/10.1016/j.gass… @Shrikhande_SV @JournalofGISurg @timpawlik

Serum EV-MDM2 DNA was significantly higher in liposarcoma patients vs controls and dropped after resection—suggesting its promise as a recurrence biomarker. journals.lww.com/annalsofsurger…

Stable OR teams contribute to better outcomes🤝✨ Each additional case done by same anesthesiologist-surgeon team 👉 ⬇️ major morbidity 🔓‼Opportunity is knocking: ⬆️outcomes by re-organizing teams How to do it? 🆕📝@JAMASurgery tinyurl.com/yx44pm96

Infact we have 6 regimens now in advanced HCC . Nivo plus IPI data ( checkmate 9DW ) updated for comparison @OncoAlert

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

May is Melanoma Cancer awareness month #SSOCommunity #Melanoma #SurgicalOncologists

April Issue: Defining Textbook Outcomes for Minimally Invasive Surgical Resection of Small Gastrointestinal #StromalTumors (GIST) of the Stomach @GrahamSpurzem @JasonSicklick @chandrajitraut rdcu.be/ei24Z @MeredithGunder @SyedAAhmad5

ICYMI: This is the 1st study to identify a prognostic association of chemotherapy dose density with overall survival in patients undergoing perioperative chemotherapy and surgery for resectable PDAC. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @SyedAAhmad5 @DavendraSohal @FlavioRochaMD @OncoAlert

Metastatic patterns stratify patients with pancreatic cancer ⁦@NatureCancer ⁦@AndrewMWaters⁩ nature.com/articles/s4301…

Excellent overview by @JeffreyFarma Annals of Surgical Oncology Practice Guidelines Series: Adjuvantand Neoadjuvant Therapy for Melanoma. @AnnSurgOncol link.springer.com/article/10.124… pubmed.ncbi.nlm.nih.gov/39495363/

December Issue: Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal #PeritonealMetastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( #CRSHIPEC ) @AllieviNiccolo rdcu.be/d5gtH @SchultzKurt @SyedAAhmad5

Signatera and possibly other ctDNA assays are NOT sufficient in the surveillance of resected colorectal cancer. The benefit may still exist but are quite limited and imaging is THE STANDARD approach in monitoring resected colorectal cancer. jamanetwork.com/journals/jaman…

December Issue: Surgical Complications After #NeoadjuvantTreatment for Borderline Resectable #PancreaticCancer : From Benchmarks to Randomized Clinical Trials @ksoreide @sanjay_HPB rdcu.be/d3mw7 @BotelhoDra @SyedAAhmad5